Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxprenolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 12/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 12/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.72 |
| ▸ | HTR2B | P41595 | 4/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxprenolol SCHEMBL16311 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL29698462 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL17464297 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL16310 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL6508035 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL30209192 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL29935146 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL123517 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL628369 | 0.97 | ADRB2 (0.95) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL11334535 | 0.89 | ADRB2 (0.78) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303474-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | ACTIMED THERAPEUTICS LIMITED (GB) | 2025-05-20 | — | — | US | disclosed |
| US-20240325322-A1 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | ACTIMED THERAPEUTICS LTD (GB) | 2024-10-03 | — | — | US | disclosed |
| US-11382876-B2 | S-enantiomerically enriched compositions of beta blockers for treating muscle weakness | ACTIMED THERAPEUTICS LTD (GB) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303474-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | SMN1; SMN2, CPT1B, ADRB1 | ADRB2 4/4885ADRB1 3/4885CYP2D6 2285/4885 |
| US-11382876-B2 | S-enantiomerically enriched compositions of beta blockers for treating muscle weakness | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885CYP2D6 1118/4885 |
| US-20240325322-A1 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, CPT1B, ADRB1 | ADRB2 4/4885ADRB1 3/4885CYP2D6 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.